Intervention

JYP0322 50 mg qd

ClinicalTrials.gov intervention label

Clinical trials1

Recruiting1

Common conditions4

Lead sponsors shown1

Clinical trials

1 shown

Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid TumorsNCT06128148 · 2022-05-04

RECRUITING

Common conditions

Brain Neoplasms1 Lung Neoplasms1 Other Protocol Specified Criteria1 Protein Kinase Inhibitors1

Leading sponsors

Guangzhou JOYO Pharma Co., Ltd1

Trial status mix

RECRUITING1

Phase mix

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.